The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 17-25 , 22 March 2004

Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment

  • Peter H Jones, MD

      Affiliations

    • Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Peter H. Jones, MD, Baylor College of Medicine, Alkek Tower, ALKT A656, Houston, Texas 77030USA.

References 

  1. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  3. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  4. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344:1383–1389
  6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143–3421
  7. National Cholesterol Education Program . Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329–1445
  8. Miettinen TA, Pyörälä K, Olsson AG, et al.  Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris (findings from the Scandinavian Simvastatin Survival Study (4S)). Circulation. 1997;96:4211–4218
  9. Knatterud GL, Rosenberg Y, Campeau L, et al.  Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. Circulation. 2000;102:157–165
  10. Sacks FM, Tonkin AM, Shepherd J, et al.  Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors (the Prospective Pravastatin Pooling Project). Circulation. 2000;102:1893–1900
  11. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am. 2000;84:23–42
  12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007
  13. Sever PS, Dahlöf B, Poulter NR, et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA) (a multicentre randomised controlled trial). Lancet. 2003;361:1149–1158
  14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults (findings from the Third National Health and Nutrition Examination Survey). JAMA. 2002;287:356–359
  15. Hu FB, Stampfer MJ, Haffner SM. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129–1134
  16. Lakka H-M, Laaksonen DE, Lakka TA, et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  17. Shepherd J, Blauw GJ, Murphy MB, et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER) (a randomised controlled trial). Lancet. 2002;360:1623–1630
  18. Gotto AMJr, Whitney E, Stein EA, et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484
  19. Rubins HB, Robins SJ, Collins D, et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  20. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106–107
  21. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–587
  22. Olsson AG, McTaggart F, Raza A. Rosuvastatin (a highly effective new HMG-CoA reductase inhibitor). Cardiovasc Drug Rev. 2002;20:303–328
  23. Jones PH, Davidson MH, Stein EA, et al.  Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin, across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–160
  24. Dujovne CA, Ettinger MP, McNeer JF, et al.  Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia [published correction appears in Am J Cardiol. 2003;91:1399]. Am J Cardiol. 2002;90:1092–1097
  25. Ballantyne CM, Houri J, Notarbartolo A, et al.  Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia (a prospective, randomized, double-blind trial). Circulation. 2003;107:2409–2415
  26. Kashyap ML, McGovern ME, Berra K, et al.  Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672–678
  27. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  28. Ridker PM, Rifai N, Rose L. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565

PII: S0002-9343(04)00073-7

doi: 10.1016/j.amjmed.2004.02.007

The American Journal of Medicine
Volume 116, Issue 6, Supplement 1 , Pages 17-25 , 22 March 2004

Article Tools

* Image Usage & Resolution